Cellid Co. Ltd (299660) - Total Assets
Based on the latest financial reports, Cellid Co. Ltd (299660) holds total assets worth ₩110.87 Billion KRW (≈ $75.13 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Cellid Co. Ltd (299660) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cellid Co. Ltd - Total Assets Trend (2015–2025)
This chart illustrates how Cellid Co. Ltd's total assets have evolved over time, based on quarterly financial data. Explore Cellid Co. Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Cellid Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Cellid Co. Ltd's total assets of ₩110.87 Billion consist of 22.0% current assets and 78.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 20.2% |
| Accounts Receivable | ₩310.14 Million | 0.3% |
| Inventory | ₩197.58 Million | 0.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩28.97 Billion | 26.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Cellid Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Cellid Co. Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cellid Co. Ltd's current assets represent 22.0% of total assets in 2025, a decrease from 90.5% in 2015.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2025, up from 14.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 4.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 26.1% of total assets.
Cellid Co. Ltd Competitors by Total Assets
Key competitors of Cellid Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Cellid Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.83 | 2.32 | 15.39 |
| Quick Ratio | 0.82 | 2.20 | 15.39 |
| Cash Ratio | 0.00 | 1.82 | 0.00 |
| Working Capital | ₩-5.00 Billion | ₩6.51 Billion | ₩25.23 Billion |
Cellid Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Cellid Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.37 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 45.7% |
| Total Assets | ₩110.87 Billion |
| Market Capitalization | $52.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cellid Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Cellid Co. Ltd's assets grew by 45.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cellid Co. Ltd (2015–2025)
The table below shows the annual total assets of Cellid Co. Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩110.87 Billion ≈ $75.13 Million |
+45.71% |
| 2024-12-31 | ₩76.09 Billion ≈ $51.56 Million |
+19.03% |
| 2023-12-31 | ₩63.92 Billion ≈ $43.32 Million |
+39.39% |
| 2022-12-31 | ₩45.86 Billion ≈ $31.08 Million |
-21.28% |
| 2021-12-31 | ₩58.26 Billion ≈ $39.48 Million |
+17.93% |
| 2020-12-31 | ₩49.40 Billion ≈ $33.48 Million |
-5.93% |
| 2019-12-31 | ₩52.52 Billion ≈ $35.59 Million |
+269.41% |
| 2018-12-31 | ₩14.22 Billion ≈ $9.63 Million |
+186.43% |
| 2017-12-31 | ₩4.96 Billion ≈ $3.36 Million |
+30.33% |
| 2016-12-31 | ₩3.81 Billion ≈ $2.58 Million |
+34.39% |
| 2015-12-31 | ₩2.83 Billion ≈ $1.92 Million |
-- |
About Cellid Co. Ltd
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) an… Read more